tradingkey.logo

CVRx Inc

CVRX

7.795USD

+0.235+3.11%
Market hours ETQuotes delayed by 15 min
203.08MMarket Cap
LossP/E TTM

CVRx Inc

7.795

+0.235+3.11%
More Details of CVRx Inc Company
CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.
Company Info
Ticker SymbolCVRX
Company nameCVRx Inc
IPO dateJun 30, 2021
CEOMr. Kevin Hykes
Number of employees206
Security typeOrdinary Share
Fiscal year-endJun 30
Address9201 West Broadway Avenue
CityMINNEAPOLIS
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code55445
Phone17634162850
Websitehttps://www.cvrx.com/
Ticker SymbolCVRX
IPO dateJun 30, 2021
CEOMr. Kevin Hykes
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Kevin Hykes
Mr. Kevin Hykes
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
35.00K
+16.67%
Mr. Joseph P. (Joe) Slattery, CPA
Mr. Joseph P. (Joe) Slattery, CPA
Lead Independent Director
Lead Independent Director
30.64K
--
Mr. Paul Verrastro
Mr. Paul Verrastro
Chief Marketing and Strategy Officer
Chief Marketing and Strategy Officer
16.84K
+1916.17%
Mr. Jared Oasheim
Mr. Jared Oasheim
Chief Financial Officer
Chief Financial Officer
15.45K
-58.75%
Ms. Martha Shadan
Ms. Martha Shadan
Independent Director
Independent Director
--
--
Dr. Mudit K. Jain, Ph.D.
Dr. Mudit K. Jain, Ph.D.
Independent Director
Independent Director
--
--
Dr. Philip B. Adamson
Dr. Philip B. Adamson
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Kevin Ballinger
Mr. Kevin Ballinger
Independent Director
Independent Director
--
--
Mr. Kirk Nielsen
Mr. Kirk Nielsen
Independent Director
Independent Director
--
--
Mr. Mitchell C. (Mitch) Hill
Mr. Mitchell C. (Mitch) Hill
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Kevin Hykes
Mr. Kevin Hykes
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
35.00K
+16.67%
Mr. Joseph P. (Joe) Slattery, CPA
Mr. Joseph P. (Joe) Slattery, CPA
Lead Independent Director
Lead Independent Director
30.64K
--
Mr. Paul Verrastro
Mr. Paul Verrastro
Chief Marketing and Strategy Officer
Chief Marketing and Strategy Officer
16.84K
+1916.17%
Mr. Jared Oasheim
Mr. Jared Oasheim
Chief Financial Officer
Chief Financial Officer
15.45K
-58.75%
Ms. Martha Shadan
Ms. Martha Shadan
Independent Director
Independent Director
--
--
Dr. Mudit K. Jain, Ph.D.
Dr. Mudit K. Jain, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
US
11.20M
90.72%
Others
1.15M
9.28%
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 23
Updated: Wed, Jul 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Johnson & Johnson Innovation-JJDC, Inc.
15.74%
New Enterprise Associates (NEA)
7.77%
Vensana Capital Management LLC
6.56%
Parkman Healthcare Partners LLC
4.72%
Gilde Equity Management Benelux B.V.
4.71%
Other
60.50%
Shareholders
Shareholders
Proportion
Johnson & Johnson Innovation-JJDC, Inc.
15.74%
New Enterprise Associates (NEA)
7.77%
Vensana Capital Management LLC
6.56%
Parkman Healthcare Partners LLC
4.72%
Gilde Equity Management Benelux B.V.
4.71%
Other
60.50%
Shareholder Types
Shareholders
Proportion
Venture Capital
30.07%
Investment Advisor
16.10%
Hedge Fund
13.70%
Investment Advisor/Hedge Fund
6.49%
Private Equity
4.71%
Individual Investor
4.29%
Research Firm
2.33%
Pension Fund
0.52%
Sovereign Wealth Fund
0.43%
Other
21.35%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
223
20.54M
78.78%
-1.58M
2025Q1
230
20.50M
79.42%
-1.80M
2024Q4
227
19.61M
76.88%
-3.77M
2024Q3
217
19.64M
83.65%
-2.97M
2024Q2
213
19.05M
87.80%
-3.48M
2024Q1
210
19.25M
90.15%
-2.13M
2023Q4
205
18.10M
86.79%
-3.35M
2023Q3
199
16.55M
79.64%
-6.10M
2023Q2
210
16.13M
77.85%
-6.03M
2023Q1
192
16.70M
81.79%
-3.37M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Johnson & Johnson Innovation-JJDC, Inc.
4.10M
15.74%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
2.03M
7.77%
--
--
Mar 31, 2025
Vensana Capital Management LLC
1.71M
6.56%
--
--
Dec 31, 2024
Parkman Healthcare Partners LLC
1.23M
4.72%
+308.35K
+33.47%
Mar 31, 2025
Gilde Equity Management Benelux B.V.
1.23M
4.71%
-136.72K
-10.01%
Feb 04, 2025
The Vanguard Group, Inc.
1.01M
3.86%
+97.21K
+10.69%
Mar 31, 2025
Emerald Advisers LLC
960.52K
3.68%
-4.19K
-0.43%
Mar 31, 2025
Jain (Mudit Kumar)
938.43K
3.6%
+1.65K
+0.18%
May 13, 2025
BlackRock Institutional Trust Company, N.A.
921.92K
3.54%
+70.36K
+8.26%
Mar 31, 2025
Balyasny Asset Management LP
407.62K
1.56%
+63.46K
+18.44%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
JPMorgan Fundamental Data Science Small Core ETF
0.09%
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
iShares Russell 2000 Value ETF
0%
Avantis US Small Cap Equity ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Vanguard US Momentum Factor ETF
0%
Avantis US Equity ETF
0%
View more
JPMorgan Fundamental Data Science Small Core ETF
Proportion0.09%
iShares Micro-Cap ETF
Proportion0.02%
iShares Russell 2000 Growth ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Vanguard US Momentum Factor ETF
Proportion0%
Avantis US Equity ETF
Proportion0%
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
KeyAI